

FIELD SAFETY NOTICE / PRODUCT NOTIFICATION

Subject: Constraint points for PTVs are potentially not correctly considered in Brainlab iPlan RT Dose

Product Reference: iPlan RT Dose version 4.0 and 4.1 (including all subversions)

Date of Notification: June 12, 2015

Individual Notifying: Julia Mehlretter, Manager MDR & Vigilance

Brainlab Identifier: CAPA-20150610-001422

Type of action: Advice regarding use of device; Device modification.



www.brainlab.com

We are writing to advise you of the following effect that has been identified for the usage of iPlan RT Dose radiation treatment planning software version 4.0 or 4.1 (including all subversions: 4.0, 4.1.0, 4.1.1, 4.1.2, 4.1.3, 4.1.4). Please note that Version 4.1 is not the latest version of iPlan RT. The purpose of this Product Notification letter is to provide you with corrective action information and to advise you of the actions Brainlab is taking to address the issue.

Effect:

The automatic monitor units (MU) calculation (normalization) potentially might be incorrect in the Brainlab iPlan RT Dose versions 4.0 and 4.1 if all of the following conditions are met:

- several PTVs are planned in the treatment plan, and
- at least one treatment group or treatment element is locked to prevent further modification, and
- for any PTV with a locked treatment group or with at least one locked treatment element assigned the dose at the 50% volume constraint point deviates more than 5% from the actual dose at 50% volume.

If in this scenario the MU calculation is refreshed (e.g. by pressing “*Refresh MU*” or leaving the prescription dialog), the software will always normalize the dose of the PTVs, which do not have a locked treatment group or treatment element assigned, to the 50% volume constraint point.

Other constraint points for the PTVs will be disregarded even if a constraint point is set “Hard Constraint” and therefore the intended prescription will not be automatically fulfilled for PTVs without a locked treatment group or locked treatment element.

The dose calculation always correctly displays the potentially unintended prescription. Therefore the potential error can be detected by looking at the isodose lines and dose volume histograms, as well as the prescription dialog. However, since the software unexpectedly might have changed the prescription (after e.g. locking a treatment element and refreshing the MU), the user may not recognize the difference during review of the treatment plan. If the plan is used for treatment and the deviation exceeds clinically acceptable limits, **this could result in ineffective radiation treatment, serious patient injury, or even death of the patient.**

Details:

iPlan RT Dose offers the *Lock and freeze functions* to prevent further modification, once a treatment group or treatment element has been correctly planned and positioned. For a locked group (also if only one element is locked) the MU of all elements are locked and cannot be changed anymore.

Constraints are used to prescribe a certain dose to a certain volume of the PTV. There are three constraint points for a PTV. The iPlan RT Dose software aims to fulfill all constraint points, but especially for forward planning (e.g. dynamic conformal arc) this may not always be possible. In this case the minimum dose constraint point is prioritized. In case a constraint has been set as hard constraint, this assigns the constraint a higher priority and the prescription renormalization is intended to be calculated so that the resulting dose volume histogram (DVH) always correctly corresponds with the hard constraint.

During any normalization of the MU, the software first attempts to fulfil the 50% volume constraint point, and only then normalizes to the prioritized constraint point (e.g. hard constraint point).

In Brainlab iPlan RT Dose 4.0 and 4.1 the software also attempts to normalize the dose of the PTV with the locked treatment group or locked treatment element assigned to the 50% volume constraint point, which cannot be achieved as MUs are locked. If the deviation between actual dose at 50% volume and the dose at the 50% volume constraint point is more than 5%, the software stops the normalization process at this step (after 30 iterations) and does not proceed with the normalization to any other constraint point for any other PTV without a locked treatment group or locked treatment element assigned.




Figure 1: Disregarded hard constraint as DVH incorrectly was normalized to 50 % volume constraint point.

User Corrective Action:

Users of the iPlan RT Dose version 4.0 and 4.1 (including all subversions) shall adhere to the following:

- **Carefully check in the Prescription dialog whether the constraint points for all PTVs/boosts are fulfilled as expected before approving and exporting, especially if the plan has several PTVs/boosts and at least one locked treatment element/group.**
- **Before approving and exporting, the entire plan needs to be reviewed. Note that at any step the dose distribution in the software reflects the dose actually delivered by the treatment plan.**



www.brainlab.com

Brainlab Corrective Action:

1. Existing potentially affected iPlan RT Dose version 4.0 or 4.1 customers receive this product notification information.
2. Brainlab will provide a software solution to prevent the described scenario from occurring. Brainlab will actively contact affected customers tentatively starting January 2016 to schedule the update.

Please advise the appropriate personnel working in your department of the content of this letter.

We sincerely apologize for any inconvenience and thank you in advance for your co-operation. If you require further clarification, please feel free to contact your local Brainlab Customer Support Representative.

Customer Hotline: +49 89 99 15 68 44 or +1 800 597 5911 (for US customers)


E-mail: support@brainlab.com (for US customers: us.support@brainlab.com)

Fax: Brainlab AG: + 49 89 99 15 68 33

Address: Brainlab AG (headquarters), Kapellenstrasse 12, 85622 Feldkirchen, Germany.

June 12, 2015

Kind Regards,



Julia Mehlretter
Manager MDR & Vigilance
brainlab.vigilance@brainlab.com

Europe: The undersign confirms that this notice has been notified to the appropriate Regulatory Agency in Europe.